Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities: 2014-2025

Historic Cash from Investing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $126.1 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Investing Activities rose 248.91% to $126.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 171.23%. This contributed to the annual value of -$228.7 million for FY2024, which is 142.60% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Cash from Investing Activities of $126.1 million as of Q3 2025, which was up 66.51% from $75.7 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Cash from Investing Activities high stood at $126.1 million for Q3 2025, and its period low was -$180.6 million during Q4 2022.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities had a median value of $40.7 million in 2023 and averaged -$1.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 11,894.34% in 2021, then tumbled by 975.93% in 2024.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash from Investing Activities stood at -$80.2 million in 2021, then plummeted by 125.16% to -$180.6 million in 2022, then climbed by 6.03% to -$169.7 million in 2023, then surged by 62.93% to -$62.9 million in 2024, then soared by 248.91% to $126.1 million in 2025.
  • Its Cash from Investing Activities was $126.1 million in Q3 2025, compared to $75.7 million in Q2 2025 and $100.1 million in Q1 2025.